This activity focuses on assessing the effects of anti-AAV neutralizing antibodies (NAbs) on the effectiveness and longevity of AAV-based gene therapies in treating individuals with hemophilia. Participants will gain insights into how these antibodies influence treatment outcomes and durability.
If you are not redirected automatically, click here.
